Want to see IN:SANOFI full AI Analyst Report?
Sanofi India Limited (SANOFI) AI Stock Analysis
Sanofi India Limited
(NSE:SANOFI)
The score is primarily supported by strong financial quality (very low leverage and strong cash generation). This is tempered by weakening revenue and margin compression, and by a mixed technical picture with the stock trading below key moving averages. Valuation is reasonable but not compelling, with the dividend yield providing support against a mid-20s P/E.
Sanofi India Limited (SANOFI) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 71.78B
- Dividend Yield
- 3.84%
- Average Volume (3M)
- 1,967
- Price to Earnings (P/E)
- 20.2
- Beta (1Y)
- 0.92
- Revenue Growth
- -5.74%
- EPS Growth
- 2.30%
- Country
- India
- Employees
- 1,097
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Pharmaceuticals
Sanofi India Limited Business Overview & Revenue Model
Company Description
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections...
Sanofi India Limited Financial Statement Overview
Summary
Strong underlying quality supported by a very low-leverage balance sheet and solid cash generation (FCF closely tracks net income, with strong 2025 FCF growth). Offsetting this, revenue weakened in 2025 and margins compressed materially into 2025, which softens operating momentum despite low financial risk.
Income Statement
68PositiveBalance Sheet
90Very PositiveCash Flow
82Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.73B | 18.37B | 20.13B | 19.96B | 27.70B | 29.57B |
| Gross Profit | 7.86B | 7.18B | 10.19B | 10.31B | 15.65B | 16.33B |
| EBITDA | 4.33B | 4.84B | 4.92B | 4.93B | 7.08B | 7.63B |
| Net Income | 3.02B | 3.27B | 4.13B | 6.03B | 6.21B | 9.44B |
Balance Sheet | ||||||
| Total Assets | 12.55B | 12.55B | 16.12B | 17.15B | 20.72B | 30.61B |
| Cash, Cash Equivalents and Short-Term Investments | 2.75B | 2.75B | 3.40B | 3.94B | 10.05B | 15.38B |
| Total Debt | 178.00M | 178.00M | 193.00M | 190.00M | 236.00M | 246.00M |
| Total Liabilities | 5.06B | 5.06B | 7.51B | 7.00B | 7.96B | 8.35B |
| Stockholders Equity | 7.49B | 7.49B | 8.61B | 10.15B | 12.76B | 22.26B |
Cash Flow | ||||||
| Free Cash Flow | 2.77B | 4.25B | 4.25B | 1.96B | 3.77B | 5.36B |
| Operating Cash Flow | 2.91B | 4.51B | 4.62B | 2.30B | 3.99B | 5.59B |
| Investing Cash Flow | -71.00M | -253.00M | -192.00M | 375.00M | 6.51B | 6.31B |
| Financing Cash Flow | -2.73B | -4.46B | -3.92B | -8.78B | -15.83B | -8.49B |
Sanofi India Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SANOFI, the sentiment is Positive. The current price of 3204.40 is above the 20-day moving average (MA) of 2972.90, above the 50-day MA of 3077.48, and below the 200-day MA of 3402.06, indicating a neutral trend. The MACD of -4.36 indicates Negative momentum. The RSI at 62.93 is Neutral, neither overbought nor oversold. The STOCH value of 77.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SANOFI.
Sanofi India Limited Peers Comparison
Overall Rating
IN:ABBOTINDIA81Outperform
IN:CIPLA79Outperform- IN:SANOFI70Outperform
IN:GLAXO68Neutral
IN:PFIZER67Neutral
IN:GLAND65Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IN:ABBOTINDIA | 81Outperform | INR 543.84B | 33.74 | ― | 2.05% | 6.29% | 11.18% |
| IN:CIPLA | 79Outperform | INR 1.11T | 38.44 | ― | 2.10% | -0.74% | -46.77% |
| IN:SANOFI | 70Outperform | INR 73.80B | 20.24 | ― | 3.84% | -5.74% | 2.30% |
| IN:GLAXO | 68Neutral | INR 420.73B | 39.56 | ― | 2.29% | 5.75% | 12.41% |
| IN:PFIZER | 67Neutral | INR 168.67B | 22.95 | ― | 2.03% | 10.69% | -9.09% |
| IN:GLAND | 65Neutral | INR 511.12B | 45.19 | ― | 0.65% | 17.57% | 46.53% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:SANOFI | Sanofi India Limited | 3204.40 | -1441.42 | -31.03% | |
| IN:ABBOTINDIA | Abbott India Limited | 25593.30 | -2826.16 | -9.94% | |
| IN:CIPLA | Cipla Ltd | 1380.00 | -117.54 | -7.85% | |
| IN:GLAND | Gland Pharma Ltd. | 3097.50 | 1140.16 | 58.25% | |
| IN:GLAXO | GlaxoSmithKline Pharmaceuticals Limited | 2483.55 | -135.33 | -5.17% | |
| IN:PFIZER | PFIZER LIMITED | 3687.05 | -1407.11 | -27.62% |
Sanofi India Limited Corporate Events
Sanofi India Faces GST Show Cause Notice Over Input Tax Credit Claims
Sanofi India Limited has disclosed that it received a show cause notice from Karnataka GST authorities alleging excess availing of input tax credit for the period April 2022 to March 2023. The Commercial Tax Officer has proposed a tax liability of Rs...
Sanofi India to Brief Investors on Q2 FY26 Unaudited Results
Sanofi India Limited has notified the stock exchanges that it will present an analyst and investor call update covering its unaudited financial results for the quarter and half year ended 30 June 2026. The company has circulated the presentation to t...
Sanofi India Publishes Q1 and Half-Year FY2026 Financial Results in Newspapers
Sanofi India Limited has reported its unaudited financial results for the quarter and half year ended 30 June 2026 and published them in leading English and Marathi newspapers in line with SEBI listing regulations. The disclosure reinforces the compa...
Sanofi India Board Clears Q2 FY2026 Results and Reshapes Key Committees
Sanofi India Limited’s board has approved the unaudited financial results for the quarter and half year ended 30 June 2026, fulfilling key regulatory requirements under SEBI’s Listing Regulations. The results, supported by a limited revie...
Sanofi India posts robust Q2 2026 results, revamps board committees
Sanofi India reported strong unaudited financial results for the quarter and half year ended 30 June 2026, driven by double-digit growth in its diabetes portfolio and solid profit momentum, underscoring the strategic importance of chronic care in its...
Sanofi India Board Clears Q2 Results, Revamps Key Committees
Sanofi India Limited, a major player in India’s pharmaceutical and healthcare sector, provides prescription drugs and related therapies and is listed on both BSE and NSE. Its governance framework features specialised committees that oversee sta...
Sanofi India Board Clears Q2 FY26 Results, Revamps Committees Ahead of CFO Exit
Sanofi India Limited’s board has approved the unaudited financial results for the quarter and half year ended June 30, 2026, which will be released to investors via stock exchange filings, newspaper extracts and the company’s website, und...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 06, 2026